Instructions for FOSAMAX (Alendronic acid) 70 mg 4 pills
Description:
White or almost white tablets, oval, with a contour image of the bone on one side and the code number "31" on the other.
1 tab.
sodium alendronate 91.37 mg,
which is what alendronic acid is 70 mg
Auxiliary substances: cellulose microcrystalline - 140 mg, lactose anhydrous - 113.4 mg, sodium croscarmellose - 3.5 mg, magnesium stearate - 1.75 mg.
4 pcs. - blisters (1) - cardboard covers (1) - cardboard packs.
ATC codes
M05BA04 Alendronic acid
Clinical-pharmacological groups / Group affiliation
Bone resorption inhibitor for osteoporosis
Active substance
alendroic acid
Pharmacotherapy group:
Bone resorption inhibitor-bisphosphonate
Pharmacological effect FOSAMAX:
Bone resorption inhibitor
The preparation stimulates osteogenesis, restores bones, progressively increases bone mineral density (regulates phosphorus-calcium exchange), promotes the formation of bone tissue with normal histological structure.
Testimony FOSAMAX:
- Treatment and prevention of osteoporosis in postmenopausal women.
- Treatment of osteoporosis in men to increase bone mass.
- Treatment of osteoporosis caused by GCS in men and women.
- Paget's disease (bone failure) in men and women.
Method of use, course and dosage FOSAMAX:
Individual, depending on the readings.
Drug interaction Alendronic acid:
The absorption of alendronic acid is impaired when taken simultaneously with other drugs FOSAMAX and calcium-containing agents.
In postmenopausal women who received estrogens, there were no side effects associated with the use of alendronic acid.
In clinical studies, there was an increase in the frequency of digestive side reactions when alendronic acid was administered at a dose of more than 10 mg/day, with acetylsalicylic acid therapy.
Application for kidney disorders
It is not recommended to use in cases of severe disorders of kidney function.
Use in children
Use in children is not recommended.
Nosology (ICD codes)
M80.0
Postmenopausal osteoporosis with pathological fracture
M80.1
Osteoporosis with pathological fracture after ovarian removal
M80.4
Drug FOSAMAX osteoporosis with pathological fracture
M80.5
Idiopathic osteoporosis with pathological fracture
M80.8
Another osteoporosis with a pathological fracture
M81.0
Postmenopausal osteoporosis
M81.1
Osteoporosis after ovarian removal
M81.4
Drug osteoporosis
M81.5
Idiopathic osteoporosis
M81.8
Other osteoporosis (senile osteopause)
M88
Paget's disease (bones) [deformative osteitis]
